FDA Orders Pfizer and Moderna to Update COVID-19 Vaccine Labels

Strategic Insights -

The U.S. Food and Drug Administration has ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines due to a rare risk of heart inflammation in teen boys and young men. The updated warnings highlight data from FDA safety monitoring and a 2023 study, which indicates a higher incidence of myocarditis and pericarditis in males aged 16 to 25. The FDA's decision comes before a U.S. Senate hearing on the downplaying and hiding of myocarditis and other adverse events associated with the COVID-19 vaccines.

Key Takeaways:

  • The FDA has ordered Pfizer and Moderna to update their warning labels on COVID-19 vaccines to highlight the rare risk of heart inflammation in teen boys and young men.
  • The updated warnings apply to males aged 16 to 25 and are based on new data from FDA safety monitoring and a 2023 study.
  • The highest estimated incidence of myocarditis and/or pericarditis was in males 16 through 25 years of age, with 38 cases per million doses.
  • The rate of heart conditions was about 8 cases per million doses for all people under 65.
  • The U.S. Centers for Disease Control and Prevention says most cases happen soon after the shot and tend to improve quickly.
  • Heart MRI scans in affected people usually showed signs of improvement over time in most people.
  • The FDA's warning also states that it is not known if these heart MRI findings might predict long-term heart effects of myocarditis, and studies are underway to investigate.

Statistics:

  • 38 cases of myocarditis and/or pericarditis per million doses in males aged 16 to 25.
  • 8 cases of myocarditis and/or pericarditis per million doses in people under 65.
  • The updated warning applies to males aged 16 to 25.
  • Both Pfizer and Moderna have 30 days to respond to the FDA's letter.

Sources:

  • CBS News, May 21, 2025.